Biogen
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
225 Binney St, Cambridge, Massachusetts,...Phone Number
(781) 464-2000Website
www.biogen.comRevenue
$9.9 BillionStock Symbol
BIIBIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
22
1
3
3
2
2
About Biogen
Biogen is a U.S.-based biotechnology company focused on discovering, developing, and commercializing therapies for serious neurological and neurodegenerative diseases. Its core portfolio includes treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and other rare neurological disorders, supported by advanced research in neuroscience, biologics, and gene-based therapies.Explore more
Biogen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biogen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Biogen launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Biogen, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Biogen
Funding: Get notified immidiatlly once Biogen has new funding data
Check if Biogen has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Biogen recently announced quarterly report
Check out if Biogen is spiking on competitors!
Click to see if Biogen had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Biogen
Compare insights from companies similar to Biogen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$29.7B
10K+
Public
$296.3M
1987
Srihari NarasimhanStrategic Initiatives Lead & To The Chief of Staff & Chief Financial Officer
$1.4B
1K - 5K
Private
$18M
1992
SG
Sean GormanDirector, Business Planning & Operations Medical Office Chief & Chief Marketing Officer
Company Profile Activity
Activity Insights
Biogen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Biogen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Biogen.
Biogen Tech Stack
A closer look at the technologies used by Biogen
Most Recent Scoops
Project
Spending/Investment, Lawsuits, Legal Affairs, Settlement
Person-Based
Pharmaceuticals, Corporate Strategy
Open Position
Open Position
Open Position
Biogen News & Media
Biogen Appoints Michael J. Parini as Chief Legal Officer
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of Biogen's Executive Committee and report to Christopher A. Viehbacher, President and Chief Executive Officer. In this role, Mr. Parini will have responsibility for oversight of Biogen’s global legal and compliance functions.LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting TOKYO and CAMBRIDGE, Mass., July 14, 2026 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB)...Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer’s disease. The data, presented at the Alzheimer’s Association International Conference (AAIC) 2026, expand upon previously reported topline results and demonstrate a combination of meaningful clinical efficacy and robust biomarker effectsFDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.)
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Biogen
Sign Up For FreeTo access detailed company insights
Biogen is a U.S.-based biotechnology company focused on discovering, developing, and commercializing therapies for serious neurological and neurodegenerative diseases. Its core portfolio includes treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and other rare neurological disorders, supported by advanced research in ne... Read More
